Learn more about HIPGEN, and meet the people behind this innovative multicenter trial which aims to develop the first regenerative therapy to improve recovery following a surgically treated hip fracture.

With the ageing of the world’s populations and a projected rise in osteoporosis-related hip fractures, it is imperative that health care providers and authorities find new ways to both reduce the numbers of hip fractures and to boost recovery following hip fracture surgery. 
Of all osteoporosis-related fractures, hip fractures cause the most morbidity and mortality, with reported mortality rates up to 20-24% in the first year after a hip fracture, and profound loss of function and independence following fracture. 

Currently no single therapy is available to address the common problem of impaired regeneration and mobility and the high mortality seen after hip fracture surgery. There is consequently a great need for the development of a new therapeutic option which will improve regenerative capacities, including improved mobility, and reduce immobility- associated diseases. IOF is honoured to be a partner in HIPGEN, an innovative project which is advancing a potential novel therapeutic option which may help address this. The clinical study, under Horizon 2020 funding, is carrying out a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled trial, designed to determine the efficacy, safety and tolerability of intramuscular injections of Allogeneic PLX-PAD Cells, for improved recovery following arthroplasty for hip fracture.  

To learn more about HIPGEN, visit the HIPGEN website and watch this informative video below:


The HIPGEN project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779293